141 related articles for article (PubMed ID: 25510196)
1. Hesperidin ameliorates behavioral impairments and neuropathology of transgenic APP/PS1 mice.
Li C; Zug C; Qu H; Schluesener H; Zhang Z
Behav Brain Res; 2015 Mar; 281():32-42. PubMed ID: 25510196
[TBL] [Abstract][Full Text] [Related]
2. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.
Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA
J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075
[TBL] [Abstract][Full Text] [Related]
3. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
4. Zerumbone ameliorates behavioral impairments and neuropathology in transgenic APP/PS1 mice by suppressing MAPK signaling.
Li L; Wu XH; Zhao XJ; Xu L; Pan CL; Zhang ZY
J Neuroinflammation; 2020 Feb; 17(1):61. PubMed ID: 32066466
[TBL] [Abstract][Full Text] [Related]
5. Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer's disease-like pathology.
Zhang Q; Yang C; Liu T; Liu L; Li F; Cai Y; Lv K; Li X; Gao J; Sun D; Xu H; Yang Q; Fan X
Neuropharmacology; 2018 Mar; 131():475-486. PubMed ID: 29241655
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
[TBL] [Abstract][Full Text] [Related]
7. Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease.
Lok K; Zhao H; Zhang C; He N; Shen H; Wang Z; Zhao W; Yin M
J Neurol Sci; 2013 Dec; 335(1-2):145-54. PubMed ID: 24095271
[TBL] [Abstract][Full Text] [Related]
8. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.
Laursen B; Mørk A; Plath N; Kristiansen U; Bastlund JF
Behav Brain Res; 2013 Mar; 240():146-52. PubMed ID: 23178660
[TBL] [Abstract][Full Text] [Related]
9. Humulus japonicus inhibits the progression of Alzheimer's disease in a APP/PS1 transgenic mouse model.
Park TS; Ryu YK; Park HY; Kim JY; Go J; Noh JR; Kim YH; Hwang JH; Choi DH; Oh WK; Lee CH; Kim KS
Int J Mol Med; 2017 Jan; 39(1):21-30. PubMed ID: 28004107
[TBL] [Abstract][Full Text] [Related]
10. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
Duffy AM; Hölscher C
Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
[TBL] [Abstract][Full Text] [Related]
11. DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice.
Yang RY; Zhao G; Wang DM; Pang XC; Wang SB; Fang JS; Li C; Liu AL; Wu S; Du GH
Pharmacol Biochem Behav; 2015 Dec; 139(Pt A):15-26. PubMed ID: 26476132
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
13. The Beneficial Effects of Combining Anti-Aβ Antibody NP106 and Curcumin Analog TML-6 on the Treatment of Alzheimer's Disease in APP/PS1 Mice.
Su IJ; Hsu CY; Shen S; Chao PK; Hsu JT; Hsueh JT; Liang JJ; Hsu YT; Shie FS
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008983
[TBL] [Abstract][Full Text] [Related]
14. Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice.
Liu MY; Wang S; Yao WF; Zhang ZJ; Zhong X; Sha L; He M; Zheng ZH; Wei MJ
Neuroscience; 2014 Jul; 273():141-51. PubMed ID: 24846616
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background.
Lok K; Zhao H; Shen H; Wang Z; Gao X; Zhao W; Yin M
Neurosci Lett; 2013 Dec; 557 Pt B():84-9. PubMed ID: 24176881
[TBL] [Abstract][Full Text] [Related]
16. Protective Effects of Forskolin on Behavioral Deficits and Neuropathological Changes in a Mouse Model of Cerebral Amyloidosis.
Owona BA; Zug C; Schluesener HJ; Zhang ZY
J Neuropathol Exp Neurol; 2016 Jul; 75(7):618-27. PubMed ID: 27251043
[TBL] [Abstract][Full Text] [Related]
17. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY
Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236
[TBL] [Abstract][Full Text] [Related]
18. Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model.
Wang Q; Xu Y; Chen JC; Qin YY; Liu M; Liu Y; Xie MJ; Yu ZY; Zhu Z; Wang W
Brain Res; 2012 Jun; 1459():15-26. PubMed ID: 22560596
[TBL] [Abstract][Full Text] [Related]
19. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
Faivre E; Hölscher C
J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
[TBL] [Abstract][Full Text] [Related]
20. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
